-Advertisement-
-Advertisement-
Hematology
FDA approves first treatment for children and adolescents with PNH
The U.S. Food and Drug Administration has approved the expanded use of ravulizumab-cwvz (Ultomiris; Alexion Pharmaceuticals) to include children >1 month of age and adolescents with paroxysmal nocturnal hemoglobinuria (PNH), according to a press release. This is the first FDA-approved medicine with children and adolescents with PNH. Rvulizumab-cwvz was approved...
Read More-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement-
Contact
© 2024 Med Journal 360™ is a trademark of International Healthcare Media, LLC. All rights Reserved